Anchored in the work of Dr. Douglas Clark, Professor of Pathology at Johns Hopkins, BioMarker Strategies is a privately-held molecular diagnostics company originally located in The Johns Hopkins Science & Technology Park in Baltimore, and now based in Rockville, MD. With a focus on making precision medicine more of a reality for patients with solid tumor cancers, the effort is to provide powerful new molecular tools and research services to guide targeted drug development and treatment selection for these patients. Focused on developing first-in-class, live-tumor-cell-based predictive tests to guide targeted drug therapy selection, pPrincipals of the firm have successfully developed the patented SnapPath™ Cancer Diagnostics System for predictive tests to guide targeted drug development and treatment selection for patients with solid tumor malignancies.
